Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of everolimus plus exemestane in postmenopausal women with ER-positive advanced breast cancer after NSAI failure
NL-OMON37575Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus and exemestane in breast cancer, sponsored by Novartis. Primary endpoint: Any adverse events. Started Jul 2012; status: active, not recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON37575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37575.